Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice.
暂无分享,去创建一个
T. Miki | Y. Tomita | N. Nonomura | H. Kanayama | T. Nakatani | M. Nozawa | H. Uemura | H. Azuma | T. Ueda | M. Tsujihata | K. Nishimura | T. Yoshioka